Loperamide

Treatment for Diarrheal diseases

Typical Dosage: 4 mg initially, then 2 mg after each loose stool, max 8 mg/day

Effectiveness
80%
Safety Score
80%
Clinical Trials
6
Participants
50K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
4 mg initially, then 2 mg after each loose stool, max 8 mg/day
Time to Effect
1 hour
Treatment Duration
1-2 days
Evidence Quality
HIGH
Number Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10
Monitoring:$800
Side Effect Mgmt:$0
Total Annual:$810
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$200/QALY
QALYs Gained
0.05
Outcome-Based Costs
Cost per Responder
$11.76
Loperamide Outcomes

for Diarrheal diseases

Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+85%
Common Side Effects
Constipation
+10%
Abdominal cramps
+5%
Nausea
+3%
Dizziness
+3%

Sources:

plos.org
escholarship.org
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
2 completed trials for Loperamide in Diarrheal diseases

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

NCT00748215COMPLETEDPHASE2
View Study
100 participants
INTERVENTIONAL
Portland, United States +1 more
Started: Feb 4, 2009

Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA

NCT06896136COMPLETEDPHASE1
View Study
36 participants
INTERVENTIONAL
Baltimore, United States
Started: Feb 11, 2025